Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434483 | 0.81 | NAAA (0.75) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL2333785 | 0.81 | NAAA (0.75) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL2334318 | 0.79 | NAAA (0.72) | NAAALMNAPAX8 | |
| SCHEMBL4982670 | 0.78 | NAAA (0.71) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL88365 | 0.78 | NAAA (0.71) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL6258955 | 0.78 | NAAA (0.97) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL9232927 | 0.77 | NAAA (0.68) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL4985814 | 0.77 | NAAA (0.68) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL2843459 | 0.77 | NAAA (0.68) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL7350719 | 0.76 | NAAA (0.72) | NAAALMNAPAX8EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130011443-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | NANOBIO CORPORATION | 2013-01-10 | — | — | US | claimed |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2012-11-01 | — | — | US | claimed |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2012-08-30 | — | — | US | claimed |
| US-20120064136-A1 | ANTI-AGING AND WRINKLE TREATMENT METHODS USING NANOEMULSION COMPOSITIONS | NANOBIO CORPORATION | 2012-03-15 | — | — | US | claimed |
| US-20100226983-A1 | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof | NANOBIO CORPORATION | 2010-09-09 | — | — | US | claimed |
| US-20100144877-A1 | Synergistic Enhancement of Calcium Propionate | VIRATOX, L.L.C. (US) | 2010-06-10 | — | — | US | claimed |
| US-20100092526-A1 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME | NANOBIO CORPORATION | 2010-04-15 | — | — | US | claimed |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2010-03-25 | — | — | US | claimed |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| US-20090143476-A1 | Antimicrobial Nanoemulsion Compositions and Methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-04 | — | — | US | claimed |
| US-20090143477-A1 | Antimicrobial Nanoemulsion Compositions and Methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-04 | — | — | US | claimed |
| EP-4486753-B1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | REVAGENIX INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12565505-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250032524-A1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | REVAGENIX INC (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4486753-A1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | Revagenix, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20050154030-A1 | Antimicrobial composition | MICROBAN PRODUCTS COMPANY (US) | 2005-07-14 | — | — | US | disclosed |
| WO-2005061228-A1 | ANTIMICROBIAL INSULATION | MICROBAN PRODUCTS COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005053616-A2 | ANTIMICROBIAL COMPOSITION | MICROBAN PRODUCTS COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-6635676-B2 | For decontaminating areas, samples, solutions, and foodstuffs colonized or otherwise infected by pathogens and microorganisms | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2003-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032524-A1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | RPN2, NRDC, MRPL21 | NAAA 204/4885LMNA 2144/4885PAX8 4443/4885 |
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | DPM1, ERG28, POLR1C | NAAA 1548/4885LMNA 3448/4885PAX8 4507/4885 |
| US-20100092526-A1 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME | CFTR, CCL11, ELANE | NAAA 1156/4885LMNA 4380/4885PAX8 4268/4885 |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | NAAA 772/4885LMNA 3805/4885PAX8 1411/4885 |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | NAAA 249/4885LMNA 3248/4885PAX8 4838/4885 |
| US-12565505-B2 | mTORC modulators and uses thereof | RICTOR, MTOR, RPTOR | NAAA 4297/4885LMNA 3995/4885PAX8 4483/4885 |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | NAAA 772/4885LMNA 3805/4885PAX8 1411/4885 |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | NAAA 249/4885LMNA 3248/4885PAX8 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.